Literature DB >> 9393587

Diagnostic and prognostic usefulness of N1,N8-diacetylspermidine and N1,N12-diacetylspermine in urine as novel markers of malignancy.

K Hiramatsu1, M Sugimoto, S Kamei, M Hoshino, K Kinoshita, K Iwasaki, M Kawakita.   

Abstract

Recently, we found N1,N8-diacetylspermidine (Ac2Spd) and N1,N12-diacetylspermine (Ac2Spm) in human urine, and noted that their amount increased significantly in patients with urogenital malignancies. Previous findings that simultaneous reference to these diacetylpolyamines is useful in distinguishing cancer patients from healthy persons were confirmed by more recent analytical data on urine samples from several cancer patients. Further examination revealed that urinary Ac2Spm and Ac2Spd tended to decrease when cancer patients were treated and entered partial remission. In cases where the Ac2Spm and Ac2Spd levels were normal or near-normal after treatments, the prognosis of the patients was generally good. In contrast, when their level remained far above the normal limits after apparently effective treatment, the prognosis of the patients was poor. When a patient is in remission for more than 3 years, urinary levels of both Ac2Spm and Ac2Spd are stabilized and stay below the normal limits, with rare exceptions. The recurrence of a cancer as well as the complication of a second one during the period of follow-up examination was accompanied by elevation of urinary diacetylpolyamines. These observations indicate that urinary Ac2Spm and Ac2Spd are useful as prognostic indicators after treatment and during follow-up examination of cancer patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9393587     DOI: 10.1007/s004320050102

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  8 in total

1.  Construction of an immunochromatographic determination system for N¹,N¹²-diacetylspermine.

Authors:  Shun-suke Moriya; Kyoko Hiramatsu; Emi Kimura; Kyoichi Matsumoto; Masao Kawakita
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

Review 2.  Polyamines. An overview.

Authors:  D M Morgan
Journal:  Mol Biotechnol       Date:  1999-06       Impact factor: 2.695

3.  The clinical usefulness of urinary N(1),N(12)-diacetylspermine (DiAcSpm) levels as a tumor marker in patients with colorectal cancer.

Authors:  Yoshifumi Nakayama; Takayuki Torigoe; Noritaka Minagawa; Koji Yamaguchi
Journal:  Oncol Lett       Date:  2012-02-29       Impact factor: 2.967

4.  Increase of N1, N12-diacetylspermine in tissues from colorectal cancer and its liver metastasis.

Authors:  Go Kuwata; Kyoko Hiramatsu; Keijiro Samejima; Kaori Iwasaki; Kei-ichi Takahashi; Koichi Koizumi; Shin-ichiro Horiguchi; Shun-suke Moriya; Masaki Kobayashi; Masao Kawakita
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-27       Impact factor: 4.553

5.  Significant correlation between urinary N(1), N(12)-diacetylspermine and tumor invasiveness in patients with clinical stage IA non-small cell lung cancer.

Authors:  Yusuke Takahashi; Hirotoshi Horio; Koji Sakaguchi; Kyoko Hiramatsu; Masao Kawakita
Journal:  BMC Cancer       Date:  2015-02-18       Impact factor: 4.430

6.  Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.

Authors:  Tik-Hung Tsoi; Chi-Fai Chan; Wai-Lun Chan; Ka-Fung Chiu; Wing-Tak Wong; Chi-Fai Ng; Ka-Leung Wong
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

Review 7.  The Emerging Clinical Role of Spermine in Prostate Cancer.

Authors:  Qiang Peng; Christine Yim-Ping Wong; Isabella Wai-Yin Cheuk; Jeremy Yuen-Chun Teoh; Peter Ka-Fung Chiu; Chi-Fai Ng
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

8.  Urinary N1, N12-diacetylspermine is a non-invasive marker for the diagnosis and prognosis of non-small-cell lung cancer.

Authors:  Yusuke Takahashi; Koji Sakaguchi; Hirotoshi Horio; Kyoko Hiramatsu; Shunsuke Moriya; Keiichi Takahashi; Masao Kawakita
Journal:  Br J Cancer       Date:  2015-10-27       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.